Nov 15, 2021 / 03:00AM GMT
Operator
Ladies and gentlemen, good day, and welcome to the Q2 FY '22 Earnings Conference Call of Glenmark Pharmaceuticals Limited. (Operator Instructions) Please note that this conference is being recorded.
I would now like to hand the conference over to Mr. Ravi Agrawal. Thank you, and over to you, sir.
Ravi Agrawal - Glenmark Pharmaceuticals Limited - IR Officer
Yes. Thank you, moderator. A warm good morning to everyone, and welcome to the Q2 FY '22 Results Conference Call of Glenmark Pharmaceuticals Limited.
Before we start the call, a review of the operations of the company. For the second quarter of FY '21/'22, Glenmark's consolidated revenue was at INR 31,474 million as against INR 29,525 million, recording an increase of 6.6% year-on-year. For the 6 months ending September 30, 2021, Glenmark's consolidated revenue was at INR 61,123 million as against INR 52,973 million, recording an increase of 15.4% year-on-year.
On to the businesses. First, the India business. Sales from the formulation business in India in Q2 FY '22 was at INR 9
Q2 2022 Glenmark Pharmaceuticals Ltd Earnings Call Transcript
Nov 15, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers